PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
August 11, 2026The Lancet

Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Previous studies suggested implantable haemodynamic monitoring might reduce heart failure hospitalisations, but rigorous trial assessment was needed.

Does management with a wireless implantable haemodynamic monitoring system reduce the rate of heart-failure-related hospitalisations in patients with NYHA class III heart failure?

Comparison

Daily wireless pulmonary artery pressure monitoring plus standard care vs standard care alone

Design

Single-blind randomised controlled trial

Follow-up

Mean 15 months (SD 7)

Key result

A wireless implantable haemodynamic monitoring system reduced heart-failure-related hospitalisations at 6 months compared to standard care (HR 0.70; 95% CI 0.60-0.84; p<0.0001).

Authors

WAWilliam T. AbrahamPAPhilip B. AdamsonRBRobert C. Bourge

Discussion

Loading...

Member takes

Overview

Wireless implantable haemodynamic monitoring significantly reduces heart-failure-related hospitalisations in patients with NYHA class III heart failure.

Key Points

  • To evaluate the effects of wireless implantable haemodynamic monitoring on hospitalizations in patients with chronic heart failure.
  • Single-blind randomized controlled trial with patients having NYHA class III heart failure.
  • Participants enrolled in 64 centers and randomly assigned to either treatment with a wireless monitoring system or standard care.
  • Primary endpoint assessed the rate of heart-failure-related hospitalizations over 6 months.
  • Treatment group had 83 heart-failure-related hospitalizations (rate 0.31) versus 120 in control (rate 0.44; HR 0.70, 95% CI 0.60-0.84, p<0.0001).
  • Overall, a 39% reduction in hospitalizations was observed for the treatment group (HR 0.64, 95% CI 0.55-0.75; p<0.0001).
  • Freedom from device-related complications was 98.6%, exceeding the 80% performance criterion (p<0.0001).

Study Design

Type

RCT (n=550)

Blinding

Single-blind

Randomization

centralised electronic system

Multicenter

Yes

Structured PICO

Does management with a wireless implantable haemodynamic monitoring system reduce the rate of heart-failure-related hospitalisations in patients with NYHA class III heart failure?

P
Population
550 patients with NYHA class III heart failure and a previous hospital admission for heart failure, followed for a mean of 15 months.
I
Intervention
Wireless implantable haemodynamic monitoring (W-IHM) system providing daily measurement of pulmonary artery pressures, added to standard of care.
C
Comparator
Standard of care alone.
O
Outcome
Rate of heart-failure-related hospitalisations at 6 months.hard clinical

Main Result

Hazard Ratio: 0.7 (95% CI 0.6–0.84)

Absolute Event Rate: 0.31% vs 0.44%

p-value: p=<0.0001

Wireless implantable haemodynamic monitoring significantly reduces heart-failure-related hospitalisations in patients with NYHA class III heart failure.

Cite This Study

Abraham et al. (2011) conducted an RCT in chronic heart failure (n=550). Wireless implantable haemodynamic monitoring (W-IHM) system vs. Standard of care alone was evaluated on Rate of heart-failure-related hospitalisations at 6 months (HR 0.70, 95% CI 0.60-0.84, p=<0.0001). A wireless implantable haemodynamic monitoring system reduced heart-failure-related hospitalisations at 6 months compared to standard care (HR 0.70; 95% CI 0.60-0.84; p<0.0001).

synapsesocial.com/papers/6a7b71e94aa654994ddc2db9https://doi.org/10.1016/s0140-6736(11)60101-3
View Full Paper
Ask AI
Bookmark
Share